Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 29, 2014, Pages 10660-10665

  Kumaresan, Pappanaicken R ^a   Manuri, Pallavi R ^a   Albert, Nathaniel D ^a   Maiti, Sourindra ^a   Singh, Harjeet ^a   Mi, Tiejuan ^a   Roszik, Jason ^a   Rabinovich, Brian ^a   Olivares, Simon ^a   Krishnamurthy, Janani ^a   Zhang, Ling ^a   Najjar, Amer M ^a   Huls, M Helen ^a   Lee, Dean A ^a,b   Champlin, Richard E ^a   Kontoyiannis, Dimitrios P ^a   Cooper, Laurence J N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Adoptive immunotherapy; Fungus; T cell therapy; 1,3 glucan

Indexed keywords

CARBOHYDRATE; CD3 ANTIGEN; DECTIN 1; GLUCAN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPERGILLUS; BIOENGINEERING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GROWTH INHIBITION; MOUSE; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADOPTIVE IMMUNOTHERAPY; FUNGUS; T-CELL THERAPY; Β-1,3-GLUCAN;

ANIMALS; ANTIGENS, CD19; ASPERGILLOSIS; ASPERGILLUS; BIOENGINEERING; CARBOHYDRATES; DEXAMETHASONE; HUMANS; HYPHAE; IMMUNOPHENOTYPING; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MICE; OPPORTUNISTIC INFECTIONS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84904632405     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1312789111     Document Type: Article

References (52)

1. Marr KA, Carter RA, Boeckh M, Martin P, Corey L (2002) Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood 100(13):4358-4366. (Pubitemid 35429674)
2. Steinbach WJ, et al. (2012) Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect 65(5):453-464.
3. Kontoyiannis DP (2011) Antifungal prophylaxis in hematopoietic stem cell transplant recipients: The unfinished tale of imperfect success. Bone Marrow Transplant 46(2):165-173.
4. Georgiadou SP, Kontoyiannis DP (2012) The impact of azole resistance on aspergillosis guidelines. Ann N Y Acad Sci 1272:15-22.
5. Brentjens RJ, et al. (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5(177):177ra138.
6. Grupp SA, et al. (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368(16):1509-1518.
7. Kochenderfer JN, et al. (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119(12):2709-2720.
8. Jena B, Dotti G, Cooper LJ (2010) Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116(7):1035-1044.
9. Kebriaei P, et al. (2012) Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther 23(5):444-450.
10. Waldorf AR, Levitz SM, Diamond RD (1984) In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. J Infect Dis 150(5):752-760. (Pubitemid 15200085)
11. Schaffner A, Douglas H, Braude A (1982) Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest 69(3):617-631. (Pubitemid 12184959)
12. Perruccio K, et al. (2005) Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 106(13):4397-4406. (Pubitemid 41775954)
13. Cooper LJ, et al. (2003) T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 101(4):1637-1644. (Pubitemid 36182545)
14. Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 20(1):70-75. (Pubitemid 34044918)
15. Kowolik CM, et al. (2006) CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66(22):10995-11004. (Pubitemid 44876999)
16. Adachi Y, et al. (2004) Characterization of beta-glucan recognition site on C-type lectin, dectin 1. Infect Immun 72(7):4159-4171. (Pubitemid 38821931)
17. Brown GD (2006) Dectin-1: A signalling non-TLR pattern-recognition receptor. Nat Rev Immunol 6(1):33-43.
18. Taylor PR, et al. (2002) The beta-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages. J Immunol 169(7):3876-3882.
19. Bowman SM, Free SJ (2006) The structure and synthesis of the fungal cell wall. Bio-Essays 28(8):799-808. (Pubitemid 44433742)
20. Werner JL, et al. (2009) Requisite role for the dectin-1 beta-glucan receptor in pulmonary defense against Aspergillus fumigatus. J Immunol 182(8):4938-4946.
21. Huls MH, et al. (2013) Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp (72):e50070.
22. Maiti SN, et al. (2013) Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother 36(2):112-123.
23. Willment JA, Gordon S, Brown GD (2001) Characterization of the human beta -glucan receptor and its alternatively spliced isoforms. J Biol Chem 276(47):43818-43823.
24. Suhoski MM, et al. (2007) Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther 15(5):981-988. (Pubitemid 46621657)
25. Geiss GK, et al. (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26(3):317-325. (Pubitemid 351355126)
26. Henson SM, et al. (2009) KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. Blood 113(26):6619-6628.
27. Voehringer D, Koschella M, Pircher H (2002) Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). Blood 100(10):3698-3702. (Pubitemid 35303941)
28. Yang XO, et al. (2008) T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 28(1):29-39.
29. Kalos M, et al. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73.
30. Adams EL, et al. (2008) Differential high-affinity interaction of dectin-1 with natural or synthetic glucans is dependent upon primary structure and is influenced by polymer chain length and side-chain branching. J Pharmacol Exp Ther 325(1):115-123. (Pubitemid 351439173)
31. Lamaris GA, et al. (2008) Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 198(2):186-192. (Pubitemid 352019283)
32. Willment JA, et al. (2003) Dectin-1 expression and function are enhanced on alternatively activated and GM-CSF-treated macrophages and are negatively regulated by IL-10, dexamethasone, and lipopolysaccharide. J Immunol 171(9):4569-4573. (Pubitemid 37310572)
33. Lionakis MS, Kontoyiannis DP (2003) Glucocorticoids and invasive fungal infections. Lancet 362(9398):1828-1838. (Pubitemid 37494764)
34. Betts MR, Koup RA (2004) Detection of T-cell degranulation: CD107a and b. Methods Cell Biol 75:497-512.
35. Ben-Ami R, Lewis RE, Leventakos K, Latgé JP, Kontoyiannis DP (2010) Cutaneous model of invasive aspergillosis. Antimicrob Agents Chemother 54(5):1848-1854.
36. Hurton LV, et al. (2013) Tethered IL-15 mutein on CD19-specific T cells sustains persistence when tumor antigen is low and can treat minimal residual disease. Mol Ther 21:S237-S237.
37. Singh H, et al. (2013) Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS ONE 8(5):e64138.
38. Klebanoff CA, et al. (2005) Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 102(27):9571-9576. (Pubitemid 40981722)
39. Pearce EL, et al. (2003) Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science 302(5647):1041-1043. (Pubitemid 37386196)
40. Intlekofer AM, et al. (2005) Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol 6(12):1236-1244. (Pubitemid 43045635)
41. Voskoboinik I, Dunstone MA, Baran K, Whisstock JC, Trapani JA (2010) Perforin: Structure, function, and role in human immunopathology. Immunol Rev 235(1):35-54.
42. Schmidt S, et al. (2011) Human natural killer cells exhibit direct activity against Aspergillus fumigatus hyphae, but not against resting conidia. J Infect Dis 203(3):430-435.
43. Kelleher P, et al. (2006) Interferon-gamma therapy in two patients with progressive chronic pulmonary aspergillosis. Eur Respir J 27(6):1307-1310. (Pubitemid 44914315)
44. Beck O, et al. (2006) Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood 107(6):2562-2569. (Pubitemid 43345583)
45. Bouzani M, et al. (2011) Human NK cells display important antifungal activity against Aspergillus fumigatus, which is directly mediated by IFN-γ release. J Immunol 187(3):1369-1376.
46. Ouyang W, Kolls JK, Zheng Y (2008) The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28(4):454-467. (Pubitemid 351471762)
47. Ivanov II, Zhou L, Littman DR (2007) Transcriptional regulation of Th17 cell differentiation. Semin Immunol 19(6):409-417. (Pubitemid 351274050)
48. Cunha C, et al. (2010) Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood 116(24):5394-5402.
49. Netea MG, et al. (2003) Aspergillus fumigatus evades immune recognition during germination through loss of toll-like receptor-4-mediated signal transduction. J Infect Dis 188(2):320-326. (Pubitemid 36898166)
50. O' Connor CM, et al. (2012) Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep 2:249.
51. Bretz C, et al. (2008) MyD88 signaling contributes to early pulmonary responses to Aspergillus fumigatus. Infect Immun 76(3):952-958. (Pubitemid 351428054)
52. Lewis RE, Albert ND, Kontoyiannis DP (2008) Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 52(11):4178-4180.